After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs says the company is at a pivot point.
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback